FORA Capital LLC Acquires New Stake in Omnicell, Inc. (NASDAQ:OMCL)

FORA Capital LLC acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL) during the first quarter, HoldingsChannel reports. The fund acquired 12,624 shares of the company’s stock, valued at approximately $369,000.

A number of other institutional investors and hedge funds have also made changes to their positions in OMCL. Panagora Asset Management Inc. acquired a new position in Omnicell during the fourth quarter worth about $1,319,000. Vanguard Group Inc. increased its holdings in Omnicell by 15.1% in the third quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company’s stock valued at $231,374,000 after buying an additional 674,824 shares in the last quarter. Pacer Advisors Inc. increased its holdings in Omnicell by 321,488.8% in the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock valued at $39,814,000 after buying an additional 1,057,698 shares in the last quarter. Cadian Capital Management LP purchased a new position in Omnicell in the fourth quarter valued at about $2,446,000. Finally, Public Sector Pension Investment Board purchased a new position in Omnicell in the third quarter valued at about $2,517,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

OMCL has been the subject of a number of research analyst reports. Benchmark reaffirmed a “buy” rating and issued a $38.00 target price on shares of Omnicell in a report on Tuesday, April 30th. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a report on Monday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $42.20.

Omnicell Price Performance

Shares of OMCL traded down $0.47 during mid-day trading on Tuesday, reaching $25.82. 115,416 shares of the company’s stock were exchanged, compared to its average volume of 519,535. The company has a quick ratio of 2.13, a current ratio of 2.38 and a debt-to-equity ratio of 0.48. The company has a 50-day simple moving average of $29.30 and a two-hundred day simple moving average of $29.96. Omnicell, Inc. has a 52-week low of $25.45 and a 52-week high of $75.07. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -56.54, a PEG ratio of 94.22 and a beta of 0.80.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.17. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. The business had revenue of $246.15 million during the quarter, compared to analysts’ expectations of $235.70 million. On average, sell-side analysts predict that Omnicell, Inc. will post 0.2 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.